Intergroupe Francophone De Cancerologie Thoracique — Sponsor Intelligence | 17 EU Trials

Filter these 17 trials by condition, phase, country and more.

Open in Search →

17 Registered trials

7 Recruiting

9 Completed trials

10 Countries active

29 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 5 Phase II/III: 1 Phase II: 10 Phase IV: 1

100%

9 of 9 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Non-small cell lung cancer stage IV 6 Non-small cell lung cancer stage IIIB 4 Pleural mesothelioma malignant 1 ALK gene rearrangement positive 1 Non-small cell lung cancer stage III 1 Pleural mesothelioma 1 Non-small cell lung cancer 1 Interstitial lung disease 1 Small cell lung cancer extensive stage 1 BRAF V600E mutation positive 1

Top IMPs

ATEZOLIZUMAB 3 CEMIPLIMAB 2 DURVALUMAB 2 NIVOLUMAB 2 PEMBROLIZUMAB 2 BINIMETINIB 1 BRIGATINIB 1 CARBOPLATIN 1 DACARBAZINE 1 DOCETAXEL 1 ENCORAFENIB 1 FIANLIMAB 1

All trials

17 total

Trial assessing treatment in patients with advanced Lung Cancer and Interstitial Lung Disease Pending

2025-522790-10-00 Phase II 1 country
Study assessing the efficacy of etoposide free chemotherapy plus durvalumab in first line extensive disease Small Cell Lung Cancer Recruiting

2023-504670-38-00 Phase II 2 countries DURVALUMAB
Trial assessing fianlimab plus cemiplimab plus chemotherapy or cemiplimab plus chemotherapy in patients with pleural mesothelioma Recruiting

2024-519208-29-00 Phase II 1 country CEMIPLIMAB; FIANLIMAB
Tarlatamab vs standard of care chemotherapy in patients with pre-treated advanced, pulmonary or gastroenteropancreatic poorly differentiated… Recruiting

2024-515948-23-00 Phase III 1 country ATEZOLIZUMAB; DACARBAZINE; DOCETAXEL; FLUOROURACIL; IRINOTECAN HYDROCHLORIDE TRI…
Trial of Tepotinib compared to Standard Treatment in Patients with Advanced MET exon 14 Mutated Non-Small Cell Lung Cancer Recruiting

2024-519971-25-00 Phase III 1 country TEPOTINIB
IFCT-2401 SPORADIC a multicenter randomized open label phase II study evaluating the efficacy and the tolerance of adding cemiplimab to Sequ… Recruiting

2024-517316-29-00 Phase II 1 country CEMIPLIMAB
Evaluating ivonescimab as a potential treatment for pleural mesothelioma patients whose cancer has returned after previous immunotherapy and… Recruiting

2024-519052-82-00 Phase II 1 country IVONESCIMAB
A phase II-III randomized trial evaluating maintenance pembrolizumab (± pemetrexed) until progression versus observation (± pemetrexed) afte… Recruiting

2024-515945-40-00 Phase II/III 1 country PEMBROLIZUMAB
IFCT-2201 ADAPTABLE A study evaluating the combination of paclitaxel-bevacizumab ± atezolizumab in patients with advanced lung cancer progre… Ended

2022-502103-30-00 Phase II 1 country ATEZOLIZUMAB
IFCT-2101 MASTERPROTOCOL ALK : Study of safety and efficacy of brigatinib and carboplatin-pemetrexed combination therapy or brigatinib monot… Ended

2023-510387-13-00 Phase II 1 country BRIGATINIB; CARBOPLATIN; PEMETREXED
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS) Ended

2024-512028-12-00 Phase II 1 country LORLATINIB
Encorafenib in combination with Binimetinib in Patients with BRAFV600E mutant metastatic Lung Cancer Ended

2024-515944-22-00 Phase II 1 country BINIMETINIB; ENCORAFENIB
A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients with Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung… Ended

2024-511185-37-00 Phase IV 2 countries
Phase III randomized trial of atezolizumab in elderly patients with advanced Non-Small-Cell Lung Cancer and receiving monthly carboplatin wi… Ended

2024-515946-17-00 Phase III 1 country ATEZOLIZUMAB
IFCT-1802 SAVIMMUNE: Immunotherapy in Patient With Poor General Condition Ended

2024-515943-44-00 Phase II 1 country DURVALUMAB
Trial comparing the continuation of nivolumab and ipilimumab (doublet immunotherapy) to observation after a first 6 months treatment by nivo… Ended

2024-514586-20-01 Phase III 1 country IPILIMUMAB; NIVOLUMAB
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Can… Ended

2024-517856-36-00 Phase III 8 countries

Showing 1–17 of 17 trials

← All sponsors A–Z